AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
| Metabolism | Hepatic via glucuronide and sulfate conjugation; CYP450 system not significantly involved. |
| Excretion | Renal (approximately 45-60% as unchanged drug and metabolites); biliary/fecal (approximately 20-25% as unchanged drug and metabolites); total urinary and fecal recovery >95%. |
| Half-life | Terminal elimination half-life of moxifloxacin is approximately 11-15 hours in patients with normal renal function; allows once-daily dosing. |
| Protein binding | Approximately 40-50% bound to serum proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 2.8 L/kg; indicates extensive tissue penetration, including into lungs, sinuses, skin, and soft tissues. |
| Bioavailability | Intravenous: 100% (complete immediate bioavailability). |
| Onset of Action | Intravenous infusion: time to near-steady-state concentrations within 3 days; clinical response typically within 24-72 hours. |
| Duration of Action | Controlled by half-life; maintains therapeutic concentrations over 24-hour dosing interval for susceptible pathogens (MIC ≤1 μg/mL). |
| Molecular Weight | 401.43 |
400 mg intravenously once daily. Infuse over 60 minutes.
| Dosage form | SOLUTION |
| Renal impairment | For GFR <30 mL/min, reduce dose to 400 mg intravenously every 48 hours. |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years. |
| Geriatric use | No routine dosage adjustment required based on age alone; monitor renal function and adjust as per renal impairment guidelines. |
| 1st trimester | Avoid; fluoroquinolones are associated with arthropathy in juvenile animals and potential fetal harm; limited human data. Use only if benefit outweighs risk. |
| 2nd trimester | Avoid; potential risk of fetal cartilage damage; consider alternative antibiotics. |
| 3rd trimester | Avoid; risk of fetal cartilage damage and neonatal adverse effects; use only if no safer alternative. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Moxifloxacin crosses the human placenta; limited data suggest fetal exposure approximately 30-50% of maternal plasma levels. |
| Breastfeeding | Moxifloxacin is excreted into breast milk in small amounts. Risk of infant arthropathy is theoretical; however, due to limited safety data, alternative agents are preferred. If used, monitor infant for diarrhea, rash, or candidiasis. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Fluoroquinolones, including moxifloxacin, are associated with an increased risk of arthropathy in juvenile animals. In humans, data from pregnant women exposed to fluoroquinolones are limited. First trimester exposure is not associated with major malformations; however, second and third trimester exposure may be linked to fetal bone and cartilage damage. Use during pregnancy should be reserved for infections where no alternatives exist. |
| Fetal Monitoring | Monitor maternal liver function tests (AST, ALT) and renal function. Assess for signs of tendonitis or tendon rupture. Fetal monitoring should include ultrasound for bone and cartilage development if exposure during second or third trimester. Monitor infant for gastrointestinal disturbances and rash if breastfeeding. |
| Fertility Effects | In animal studies, moxifloxacin did not impair fertility. Human data are lacking. Potential for transient effects on sperm motility or quality, but no conclusive evidence of significant reproductive impairment. |
■ FDA Black Box Warning
Fluoroquinolones, including moxifloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients older than 60 years, those taking corticosteroids, and those with kidney, heart, or lung transplants. Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid use in patients with known history of myasthenia gravis.
| Common Effects | fluid replacement |
| Serious Effects |
Hypersensitivity to moxifloxacin or any fluoroquinoloneHistory of tendon disorders with fluoroquinolone therapyPatients with known QT prolongation or uncorrected hypokalemiaConcurrent use with other drugs that prolong QT interval
| Precautions | May prolong QT interval; avoid in patients with known QTc prolongation, uncorrected hypokalemia, or receiving class IA or III antiarrhythmics. Use with caution in patients with CNS disorders (e.g., epilepsy). Discontinue if signs of tendon pain, inflammation, or rupture occur. May cause peripheral neuropathy. Use with caution in patients with renal impairment. Avoid in patients with known hypersensitivity to fluoroquinolones. |
| Food/Dietary | No specific food interactions. However, avoid alcohol as it may increase risk of dizziness and gastrointestinal side effects. Keep well hydrated. |
| Clinical Pearls | AVELOX (moxifloxacin) in sodium chloride 0.8% is a fluoroquinolone antibiotic for intravenous use. Avoid rapid infusion; administer over 60 minutes to reduce risk of infusion-related reactions. Monitor for QT prolongation, especially in patients with electrolyte disturbances or on antiarrhythmics. Avoid in patients with known aortic aneurysm or history of tendinopathy. Use caution in elderly and those with renal impairment. Not recommended for patients with myasthenia gravis due to risk of exacerbation. |
| Patient Advice | This medication is given intravenously (IV) and must be infused slowly over at least 60 minutes. · You may experience side effects like nausea, diarrhea, dizziness, or headache. Report severe or persistent symptoms. · Watch for signs of tendon pain or swelling, especially in the shoulder or calf. Stop the medication and seek medical attention if this occurs. · Avoid driving or operating machinery if you experience dizziness or vision changes. · Tell your doctor if you have a history of heart rhythm problems, seizures, or low potassium/magnesium levels. · Use sunscreen and protective clothing to avoid sun sensitivity reactions while on this medication. |
Loading safety data…